Market Overview:
The global pharyngeal cancer therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of pharyngeal cancer, rising awareness about pharyngeal cancer and its treatment options, and the launch of novel therapies for the treatment of this disease. The global pharyngeal cancer therapeutics market can be segmented on the basis of type into targeted therapy and chemotherapy. On the basis of application, it can be segmented into hospital, clinic, and other segments. Geographically, it can be divided into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . Some key players operating in this market are AstraZeneca plc., F Hoffmann-La Roche Ltd., Eli Lilly and Company,, Bristol-Myers Squibb Company,, Pfizer Inc.
Product Definition:
Pharyngeal cancer therapeutics is a branch of oncology that deals with the diagnosis and treatment of cancers that affect the pharynx. The pharynx is a tube-like structure in the throat that carries food and air to and from the lungs. Cancers of the pharynx can be divided into two main categories: squamous cell carcinoma and non-squamous cell carcinoma. Squamous cell carcinomas are cancers that develop from cells called squamous cells, which line many organs in the body. Non-squamous cell carcinomas are cancers that develop from other types of cells found in the pharynx. Treatment for pharyngeal cancer depends on factors such as tumor size, location, stage of disease, and health status of the patient.
Targeted Therapy:
Targeted therapy is a branch of cancer treatment that focuses on specific tissues or organs affected with cancer. It's major application includes treating the brain, lungs, and breast cancers. The factors that propel the growth of targeted therapy include growing base of geriatric population and rising awareness about this form of treatment among patients & physicians.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy includes a group of medical procedures used to treat cancer. The most common types of chemotherapies include alkylating agents, cytotoxic agents, plant derivatives, and antimetabolites. Some other types include monoclonal antibodies (MAbs), small molecule drugs, and polyene chain reaction (PCR).
Application Insights:
Based on application, the global market is segmented into hospital, clinic and others. Hospital dominated the overall market in terms of revenue in 2017 owing to high usage rates of chemotherapy drugs for treatment against pharyngeal cancer and increasing prevalence of the disease. Increasing number of hospitals offering comprehensive healthcare services along with rising demand for effective yet affordable treatments are factors contributing to its dominance over other applications.
The clinic application segment is expected to witness significant growth during the forecast period owing to growing awareness about early diagnosis and availability of advanced treatment options such as radiation therapy at an affordable cost coupled with government initiatives encouraging private clinics to join hands in treating patients diagnosed with head & neck cancer. Other applications include pharyngeal surgery centers, home care services and end-of-life care planning facilities (palliative).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high investment in research & development, and availability of effective treatment methods for advanced cancers such as pharyngeal cancer. The region is expected to maintain its dominance throughout the forecast period owing to factors such as favorable government initiatives and increasing healthcare expenditure. For instance, according to a study published by NCBI, North America accounted for approximately 27% share of total funding received by oncology drug discovery companies between 2006-2011. Asia Pacific is anticipated to witness lucrative growth over the forecast period due rising awareness about early diagnosis coupled with rapidly improving healthcare infrastructure especially in emerging countries like China & India which are major markets for this region like Indonesia & Malaysia respectively (NCBI).
The key companies involved in this market include Pfizer Inc.
Growth Factors:
- Increasing incidence of pharyngeal cancer
- Growing demand for better and more effective therapies
- Rising awareness about pharyngeal cancer and its treatment options
- Technological advancements in the field of pharyngeal cancer therapeutics
- Growing number of clinical trials for new pharyngeal cancer therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharyngeal Cancer Therapeutics Market Research Report
By Type
Targeted Therapy, Chemotherapy
By Application
Hospital, Clinic, Other
By Companies
AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Roche, Merck & Co., Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Pharyngeal Cancer Therapeutics Market Report Segments:
The global Pharyngeal Cancer Therapeutics market is segmented on the basis of:
Types
Targeted Therapy, Chemotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Roche
- Merck & Co., Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Highlights of The Pharyngeal Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Targeted Therapy
- Chemotherapy
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharyngeal Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharyngeal cancer therapies are treatments that aim to kill or shrink the tumor in the pharynx.
Some of the major companies in the pharyngeal cancer therapeutics market are AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Roche, Merck & Co., Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd..
The pharyngeal cancer therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharyngeal Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharyngeal Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharyngeal Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharyngeal Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharyngeal Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Pharyngeal Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Pharyngeal Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Pharyngeal Cancer Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pharyngeal Cancer Therapeutics Market Size Forecast by Type
5.2.1 Targeted Therapy
5.2.2 Chemotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pharyngeal Cancer Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pharyngeal Cancer Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pharyngeal Cancer Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pharyngeal Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Pharyngeal Cancer Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pharyngeal Cancer Therapeutics Market Size Forecast by Type
9.6.1 Targeted Therapy
9.6.2 Chemotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pharyngeal Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Pharyngeal Cancer Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pharyngeal Cancer Therapeutics Market Size Forecast by Type
10.6.1 Targeted Therapy
10.6.2 Chemotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pharyngeal Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pharyngeal Cancer Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pharyngeal Cancer Therapeutics Market Size Forecast by Type
11.6.1 Targeted Therapy
11.6.2 Chemotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pharyngeal Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Pharyngeal Cancer Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pharyngeal Cancer Therapeutics Market Size Forecast by Type
12.6.1 Targeted Therapy
12.6.2 Chemotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pharyngeal Cancer Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pharyngeal Cancer Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pharyngeal Cancer Therapeutics Market Size Forecast by Type
13.6.1 Targeted Therapy
13.6.2 Chemotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pharyngeal Cancer Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pharyngeal Cancer Therapeutics Market: Competitive Dashboard
14.2 Global Pharyngeal Cancer Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca Plc
14.3.2 Bristol-Myers Squibb Co.
14.3.3 Eli Lilly and Co.
14.3.4 Roche
14.3.5 Merck & Co., Inc.
14.3.6 Mylan NV
14.3.7 Pfizer Inc.
14.3.8 Sanofi
14.3.9 Sun Pharmaceutical Industries Ltd.
14.3.10 Teva Pharmaceutical Industries Ltd.
